IDH1 and glioblastoma: The risk scores were lower in GBM patients with IDH1-mutant type, MGMT promoter methylated and G-CIMP subgroups than the IDH1-wild type (wt), MGMT promoter unmethylated and non G-CIMP ones of TCGA cohort, respectively (Figures 3A–C).